BioSyent

BioSyent EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioSyent (RX.V) as of Oct 6, 2026 is 11.31 M CAD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 9.65 M CAD — a change of 17.18% (higher).

EBITDA

11.31 MCAD

YoY

17.18%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioSyent is 2026 11.31 M CAD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioSyent was 2025 9.65 M CAD. It decreases by 17.18% higher compared to the previous year.

The BioSyent EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
6.98 M CAD
Jan 1, 2019
5.68 M CAD
Jan 1, 2020
5.54 M CAD
Jan 1, 2021
8.64 M CAD
Jan 1, 2022
7.43 M CAD
Jan 1, 2023
7.99 M CAD
Jan 1, 2024
9.65 M CAD
Jan 1, 2025
11.31 M CAD
The BioSyent EBITDA history
YEAREBITDAYoY
11.31 MCAD+17.18%
9.65 MCAD+20.84%
7.99 MCAD+7.49%
7.43 MCAD-13.97%
8.64 MCAD+55.95%
5.54 MCAD-2.45%
5.68 MCAD-18.63%
6.98 MCAD-0.85%
7.04 MCAD+19.32%
5.90 MCAD+15.40%
5.11 MCAD+19.20%
4.29 MCAD—
Access this data via the Eulerpool API

BioSyent Stock analysis

What does BioSyent do? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioSyent stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioSyent is 11.31 M CAD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of BioSyent changed from 9.65 M CAD to 11.31 M CAD, representing a 17.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) BioSyent since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s BioSyent historically and in real time.

Access this data via the Eulerpool API

Income Statement — BioSyent

All Key Metrics — BioSyent